In this review, we provided a balanced view of glycation in cancer progression by modulating several cell signaling pathways and discussed the role of deglycation by FN3K and the need for the development of FN3K inhibitors to maintain Nrf2 in glycated state in order to effectively treat advanced cancers. This evidence concerns the gene FN3K and cancer.